CLINICAL COURSE OF PERIMENOPAUSAL PERIOD IN WOMEN WITH HYPERANDROGENISM SYNDROME
Keywords:
hyperandrogenism, hormones, ovaries, adrenal glands, reproductive disordersAbstract
Hyperandrogenism is a disorder of endocrine status caused by excess production of androgens. The syndrome is a consequence of increased androgen production both in the ovaries and adrenal glands. However, such a division is very arbitrary, as increased production of androgens in the adrenal glands may increase production in the ovaries and vice versa. Androgens in women are synthesized by ovaries, adrenal glands and peripheral tissues, which also participate in metabolism. The set of androgens in both women and men includes dehydroepiandrosterone-sulfate, dehydroepiandrosterone, androstenedione, testosterone and 5-alpha-dihydrotestosterone (5-alpha-DHT). Still, unlike men, women have a higher concentration of the first three hormones than the last two. Androgen synthesis in the adrenal glands in women is regulated by adrenocorticotropic and in the ovaries by luteinizing hormone (LH) and some other intraglandular autoparacrine mechanisms. According to recent studies, in addition to the basic biological, previously commonly known effects of androgens, their new mechanisms of influence on the female body have been discovered.
References
Brown D.L., Henrichsen T.L., Clayton A.C., Hudson S.B., Coddngton C.C., Vella A. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med 2009; 28: 587—593.
Buggs C., Rosenfield R.L. Polycystic ovary syndrome in adolescence. Endocrinol Metabol Clin North Am 2005; 34: 677—705.
Cordera F., Grant C., van Heerden J., Thompson G., Young W. Androgensecreting adrenal tumors. Surgery 2003; 134: 874—880.
Davison S.L., Bell R., Donath S., Montalto J.G., Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metabol 2005; 90: 3847—3853.
Diamanti-Kandarakis E., Lambrinoudaki I., Economou F. Androgens associated with advanced glycation end-products in postmenopausal women. Menopause 2010; 17: 1182—1187.
Dorgan J.F., Stanczyk F.Z., Kahle L.L., Brinton L.A. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2011; 12: R98.
Kaltsas G.A., Isidori A.M., Kola B.P. The value of the low-dosedexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metabol 2003; 88: 2634—2643.
Klotz R.K., Muller-Holzner E., Fessler S. Leydig-celltumor of the ovary that responded to GnRH-analogue administration — case report and literature review. Exp Clin Endocrinol Diabetol 2010; 118: 291—297.
Krug E., Berga S.L. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in the climacteric ovary. Obstet Gynecol 2002; 99: 893—897.
Martin K.A., Chang R.J., Ehrmann D.A., Ibanez L., Lobo R.A., Rosenfield R.L., Shapiro J., Montori V.N., Swiglo B.A. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2008; 93: 1105—1120.
Nieman L.K. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metabol 2010; 95: 4106—4113. 15. Norman R.J.D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet 2007; 370: 685—697.
Rittmaster R.S. Polycystic ovary syndrome, hyperthecosis and the menopause. Clin Endocrinol (Oxford) 1997; 46: 129—130.
Rosner W., Auchus R.J., Azziz R., Sluss P.M., Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metabol 2007; 92: 405—413.
Rothman M.S., Carlson N.E., Xu M. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011; 76: 177—182.
Rothman M.S., Wierman M.E. How should postmenopausal androgen excess be evaluated? Clin Endocrinol 2011; 75: 160—164.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41—47.
Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D., Kelsey S.F., Kip K.E., Cooper-Dehoff R.H., Johnson B.D., Vaccarino V., Reis S.E. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health — National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metabol 2008; 93: 1276—1284.
Speiser P.W., Azziz R., Baskin L.S., Ghizzoni L., Hensle T.W., Merke D.B. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2010; 95: 4133—4160.
Thompson G.B., Young W.F.Jr. Adrenal incidentaloma. Curr Opin Oncol 2003; 15: 84—90.
Waggoner W., Boots L.R., Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol 1999; 13: 394—400.
Wild R.A., Carmina E., Diamanti-Kandarakis E., Dokras A., Escobar-Morreale H.F., Futterweit W., Lobo R., Norman R.J., Taibott E., Dumesic D.A. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metabol 2010; 95: 2038—2049.
Winters S.J., Talbott E., Guzick D.S., Zborowsky J., McHugh K.P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000; 73: 724—729.
Yetkin D.O., Demirsoy E.T., Kadioglu P. Pure leydig cell tumour of the ovary in a post-menopausal patient with severe hyperandrogenism and erythrocytosis. Gynecol Endocrinol 2011; 27: 237—240.
